A Phase 1 Study to Assess the Pharmacokinetics of Different Multiple Dose Regimens of CT1812 in Older Healthy Volunteers
Latest Information Update: 14 Apr 2023
At a glance
- Drugs Zervimesine (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Cognition Therapeutics
Most Recent Events
- 16 Jun 2022 Status changed from recruiting to completed.
- 22 Feb 2022 New trial record